Mayo Clinic Study Finds Younger Men With Erectile Dysfunction At Double Risk Of Heart Disease
Men who experience erectile dysfunction between the ages of 40 and 49 are twice as likely to develop heart disease than men without dysfunction, according to a new Mayo Clinic study. Researchers also found that men with erectile dysfunction have an 80 percent higher risk of heart disease. "The highest risk for coronary heart disease was in younger men," says researcher Jennifer St. Sauver, Ph.D.
Source: www.medicalnewstoday.com

Adult Male Circumcision Not Linked To Sexual Dysfunction
The World Health Organization recommends male circumcision as an important element in HIV prevention programs, and the procedure is promoted in high-risk heterosexual populations. While the benefits of circumcision are well-documented (they also include reduced rates of urinary tract infection, penile cancer, and cervical cancer and chlamydia in female partners), there remains a concern that adult circumcision may impair sexual function.
Source: www.medicalnewstoday.com

Viagra's Other Talents: To Help A 'Signaling' Protein Shield The Heart From High Blood Pressure Damage
Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein. The team's findings, to be published in the Journal of Clinical Investigation online Jan.
Source: www.medicalnewstoday.com

Bicycle Seat Design Can Directly Affect A Man's Sexual Function
Long suspected by the 5 million recreational bike riders and sexual medicine experts, bicycle seat design-shorter noseless seats versus the standard protruding nose extended seat-can directly affect a man's sexual function, based on the nation's first prospective study of healthy policemen riding bikes on the job. The study is published in the current issue of the Journal of Sexual Medicine. Dr.
Source: www.medicalnewstoday.com

FDA advisory committee recommends approval for seizure treatment Sabril.
FDA advisory committee recommends approval for seizure treatment Sabril. The Chicago Tribune (1/8, Japsen) reports, “Ovation Pharmaceuticals Inc. said Wednesday evening that an advisory committee to the U.S. Food and Drug Administration voted unanimously to recommend the company’s Sabril (vigabatrin) seizure treatment be approved by the agency.” The company “said Sabril was endorsed by the advisory [...]
Source: feeds.feedburner.com

Male Sexual Function Comes Back Faster With New Surgical Procedure Developed At CINJ
A new robotic surgical technique developed at The Cancer Institute of New Jersey (CINJ) for the removal of all or part of the prostate gland is showing what investigators call a "dramatic improvement" in a male's sexual potency rate. The results were recently presented at the 26th World Congress Endourology meeting in Shanghai, China. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School and has also developed a Center of Excellence for robotic surgery.
Source: www.medicalnewstoday.com

VIVUS Initiates Second Pivotal Phase 3 Trial Of Avanafil For Treatment Of Erectile Dysfunction
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced it has initiated a second pivotal Phase 3 study of avanafil, its investigational new drug for the treatment of erectile dysfunction (ED). Avanafil is a next-generation, fast-acting, selective, investigational oral phosphodiesterase type 5 (PDE5) inhibitor.
Source: www.medicalnewstoday.com

Fewer Vagal Nerve Stimulation Operations In Scotland Than England And Wales
Compared with the rest of the UK, fewer people in Scotland are fitted with vagal nerve stimulation (VNS) devices to treat their epilepsy. To discover the reasons, Epilepsy Scotland has invited two clinicians, Dundee-based Richard Roberts and Richard Selway from London, to explore VNS from both sides of the border. This free debate for health professionals is Friday 13 February in Glasgow's Teachers Building from 6.30-8.30pm.
Source: www.medicalnewstoday.com

PSD502 For Premature Ejaculation - Positive Outcomes From European Phase III Pivotal Trial
Plethora Solutions Holdings PLC ("Plethora" or the "Company", AIM: PLE), the specialist developer of products for the treatment and management of urological disorders, announces that its European Phase III double-blind placebo controlled study of PSD502 for the treatment of premature ejaculation (PE) has met its three co-primary endpoints of Intra-vaginal Ejaculation Latency Time ('IELT') and Index of Premature Ejaculation ('IPE'; Ejaculatory Control and Sexual Satisfaction domains).
Source: www.medicalnewstoday.com